$577M Award For Asahi In Drug Licensing Row Trimmed

Law360, New York (July 29, 2011, 5:21 PM EDT) -- A California state judge has cut $70 million from Asahi Kasei Pharma Corp.'s $577 million win in a suit claiming Actelion Ltd. bought CoTherix Inc. in order to undermine a drug licensing pact and preserve its monopoly on a hypertension treatment, the defendant announced Friday.

The May verdict followed a contentious three-month trial in which Allschwil, Switzerland-based Actelion was accused of acquiring CoTherix and then interfering with the target's agreement with Asahi to develop a hypertension drug called Fasudil.

Actelion had asked Judge Marie S. Weiner...
To view the full article, register now.